Search clinical trials for: Budesonide 200 microgram/Puff, HFA MDI

Total 20 results

Intech Biopharm Ltd.
Peking University People's Hospital; Beijing Friendship Hospital; The Second... and other collaborators

Completed

Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients

Asthma

China
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Korea, Republic of, Argentina, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Canada, India, Bulgaria, Poland
AstraZeneca
Parexel

Completed

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca
Parexel

Completed

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen (Allergen)

Asthma

Canada
Intech Biopharm Ltd.

Completed

Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers

Asthma

Taiwan
AstraZeneca

Completed

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Asthma

United States, Puerto Rico
AstraZeneca

Completed

Titratable Dosing in Moderate to Severe Asthmatics

Asthma
Lupin, Inc.

Completed

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

Mild Persistent Asthma

United States
Boehringer Ingelheim

Completed

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Organon and Co

Completed

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (SPIRO)

Asthma
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
Orion Corporation, Orion Pharma

Completed

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (EASYRELIEF)

Asthma

Finland
Intech Biopharm Ltd.

Completed

Efficacy Study of SYN006 HFA MDI in Asthma Patients

Asthma

Taiwan
AstraZeneca

Completed

Budesonide / Formoterol in Treatment of Exacerbations of COPD

Chronic Obstructive Pulmonary Disease

Netherlands
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Chronic Obstructive Pulmonary Disease

France
Organon and Co

Completed

Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

Bronchial Asthma

Spain, Italy, Russian Federation, Ukraine
Organon and Co

Withdrawn

Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)

Asthma
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Anal Canal Cloacogenic Carcinoma | Stage III Anal Cancer AJCC v8 | Anal Margin Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Anal Basaloid Squamous Cell Carcinoma

United States, Canada

3

Subscribe